NovoCodex Biopharmaceuticals Co.
Latest round
- Series C
Last raised
- Mar 2026
Total raised
- $121M
Investors
- 13
About NovoCodex Biopharmaceuticals Co.
, Ltd., provides innovation drugs for cancer. The company has 96 employees, including 13 doctors and 24 masters. The company was selected as a science and technology-based small and medium-sized enterprise in Zhejiang Province in 2020, and received the Shaoxing City 2020 High Quality Contribution Award and other honors., Ltd. The firm currently provides innovative biological drug anti-HER2, which is the first to use unnatural amino acids to insert proteins into the protein to achieve precise coupling of toxins on the monoclonal antibody molecules for the treatment of HER2 Positive recurrent breast cancer and gastric cancer. At present, the breast cancer registration clinical research of ARX788 is in the enrollment stage, and the gastric cancer registration clinical research is actively preparing. ARX305 is currently in the pre-clinical evaluation and research stage, and it is expected to submit an IND registration application in 2022. In addition, the technology platform that the company have many products under development. The company's revenue is generated by providing innovative biological drugs.
Who invested in NovoCodex Biopharmaceuticals Co.
13 investors across 3 rounds
See all investors in NovoCodex Biopharmaceuticals Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about NovoCodex Biopharmaceuticals Co.
Who invested in NovoCodex Biopharmaceuticals Co.?
NovoCodex Biopharmaceuticals Co. has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NovoCodex Biopharmaceuticals Co. raised?
NovoCodex Biopharmaceuticals Co. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did NovoCodex Biopharmaceuticals Co. last raise money?
NovoCodex Biopharmaceuticals Co.'s most recent round on record is a Series C, in Mar 2026.
What does NovoCodex Biopharmaceuticals Co. do?
NovoCodex Biopharmaceuticals Co. is a pharmaceuticals company.
Where is NovoCodex Biopharmaceuticals Co. headquartered?
NovoCodex Biopharmaceuticals Co. is headquartered in Shaoxing, China.
Which VCs invest in companies like NovoCodex Biopharmaceuticals Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at NovoCodex Biopharmaceuticals Co.'s stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like NovoCodex Biopharmaceuticals Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.